ClinicalTrials.gg
CompletedNCT06337110Updated Oct 4, 2024

A Study Investigating the Movement of Lu AF28996 Into, Through, and Out of the Body of Healthy Men

A Phase 1 interventional study of Lu AF28996 in Healthy Participants, sponsored by H. Lundbeck A/S. Completed at 1 site in United Kingdom. Open to male participants aged 35 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-04.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
35 Years to 60 Years
Sex
Male
01

Study summary

The main goal of this study is to learn about how Lu AF28996 moves into, through, and out of the body after a single dose is given to healthy male participants.

02

Conditions studied

  • Healthy Participants
03

In context

Lead sponsor

H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • The participant has a (BMI) >=18.5 and \<=30 kilograms per square meter (kg/m\^2) and body weight ≥60 kg at the Screening Visit and at the Baseline Visit.
  • The participant has a resting supine pulse >=50 and \<=100 beats per minute (bpm) at the Screening Visit and at the Baseline Visit.
  • The participant is, in the opinion of the investigator, generally healthy based on medical history, a physical examination, a neurological examination, vital signs, an (ECG), and the results of the clinical chemistry, haematology, urinalysis, serology, and other laboratory tests.

Key Exclusion Criteria:

  • The participant has participated in a clinical trial \<30 days prior to the Screening Visit.
  • The participant has taken any medicinal product \<3 months or \<5 half-lives of that product, whichever is longest, prior to the first dose of investigational medicinal product (IMP).
  • Participants with exposure to significant diagnostic or therapeutic radiation (eg, serial X-ray, computed tomography scan, barium meal) or current employment in a job requiring radiation exposure monitoring within 12 months prior to check-in.

Other protocol-defined criteria apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Lu AF28996

    Participants will receive a single oral dose of Lu AF28996.

    Drug: Lu AF28996

Interventions

  • Oral solution containing radiolabelled \[14C\]-Lu AF28996.

06

What researchers measure

Primary outcomes

  1. Total Recovery of the Administered Radiolabelled Drug-related Material (Percentage of Dose in Urine and Faeces)

    Time frame: From baseline (Day -1) up to 23 days post-dose

  2. AUC0-infinity: Area Under the Plasma Concentration Curve of Radiolabelled Drug-related Material from Zero to Infinity

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  3. Cmax: Maximum Observed Plasma Concentration of Radiolabelled Drug-related Material

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  4. Tmax: Nominal Time Corresponding to the Occurrence of Cmax of Radiolabelled Drug-related Material

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  5. T½: Apparent Elimination Half-life of Radiolabelled Drug-related Material

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  6. AUC0-infinity of Lu AF28996

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  7. Cmax of Lu AF28996

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  8. Tmax of Lu AF28996

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

  9. T½ of Lu AF28996

    Time frame: From date of dosing (Day 1) up to 23 days post-dose

07

Study locations

1 site
  • Fortrea Clinical Research Unit Ltd
    Leeds, LS11 9EH, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in May 2024, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2024
First posted
Mar 29, 2024
StartActual
Apr 10, 2024
Primary completionActual
May 11, 2024
CompletionActual
May 11, 2024
Last update
Oct 4, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06337110
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Mar 29, 2024
Start date
Apr 10, 2024
Primary completion
May 11, 2024
Completion
May 11, 2024
Last update
Oct 4, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lu AF28996

Start the discussion